Apellis Pharmaceuticals APLS provided third-quarter 2023 preliminary revenues guidance for its recently launched drug, Syfovre (pegcetacoplan injection), for the treatment of geographic atrophy ...

Apellis Pharmaceuticals, Inc. (APLS) reported $166.8 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.2%. EPS of -$0.74 for the same period compares ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other stocks that will bounce back. Major US indexes finished in the green on ...